GB2249027A — Use of macrolide compounds for hepatic failure

USPTO Abstract

The use of macrolide compounds of the following formula for the prophylactic and/or therapeutic treatment of hepatic failure:- <IMAGE> wherein [R<1> and R<2>], [R<3> and R<4>], [R<5> and R<6>] are hydrogen or form a direct bond or R<2> is alkyl; R<7> is H, OH, protected hydroxy or O-alkyl, or R<1> and R<7> represent =0; R<8> and R<9> are H or OH; R<10>H, alkyl, or alkenyl; X is O, (H, OH), (H, H), or -CH2O-; Y is O, (H, OH), (H, H), N-NR<11>R<12> or N-OR<13>; R<11> and R<12> are H, alkyl, aryl or tosyl; R<13>, R<14>, R<15>, R<16>, R<17>, R<18>, R<19>, R<22> and R<23> are H or alkyl; R<20> and R<21> are O, or OH, or O-alkyl; or, R<20> and R<21> form an epoxide ring; n is 1, 2, or 3; or Y, R<10> and R<23>, together with the carbon atoms to which they are attached, form a 5- or 6- membered N-, S- or O- containing heterocyclic ring, which is optionally saturated and substituted; or a pharmaceutically acceptable salt thereof.